Nkarta, Inc.

Team Nkarta’s clinical leaders recently traveled to Houston for Kidney Week, the world’s largest annual #nephrology conference, hosted by the American Society of Nephrology (ASN). We focused on introducing a new therapeutic modality, CAR-NK, to nephrologists and discussed the scientific potential of #celltherapy to benefit their patients. Nkarta is in the clinic with an investigational cell therapy with the potential to advance future treatment options for patients living with #lupusnephritis and primary membranous nephropathy. We came away from ASN with new opportunities for KOL partnerships, trial participation, and site expansion. To learn more about our clinical trial in these indications, visit the Ntrust-1 website: https://www.ntrust1.com/ Providers seeking more information about our studies or the opportunity to speak to a member of our clinical team should visit our provider information page: https://lnkd.in/gjeNhHPj

At Nkarta, we’re reimaging our future with a laser focus on #autoimmunediseases such as #scleroderma, #myositis and #lupus. Our goal remains the same: harness the power of natural killer (NK) #celltherapy to fundamentally change how B cell-mediated conditions are treated by targeting the underlying cause of these diseases, rather than only addressing the symptoms. Beyond scientific discovery, we are equally committed to ensuring equitable access to clinical trials that make these breakthroughs possible. Innovation matters most when everyone can benefit from it. Read more about Nkarta’s efforts to create a new way forward for people living with #autoimmune disease on our revitalized website that went live today with fresh content: https://www.nkartatx.com/

Thank you to everyone who joined us at our poster session during the American College of Rheumatology annual meeting. We’re inspired by the meaningful conversations and insightful questions from fellow #scientists, #clinicians and #advocates. Sharing our latest data on NKX019, an allogeneic, off-the-shelf CAR NK-cell therapy, reinforced the power of collaboration in advancing new options for people living with #autoimmune diseases. Our findings underscore the potential of NKX019 to overcome key barriers faced by current therapies, with promising preclinical and clinical results supporting its role as a novel approach for B-cell driven autoimmune disease. We’re grateful for the opportunity to engage with the #rheumatology community and look forward to continuing the dialogue as we work to bring innovative #celltherapies to more patients. Let’s keep the momentum going together. Learn more about our poster findings: https://lnkd.in/gdXJ66ia #ACR25 #CellTherapy #AutoimmuneDisease #Rheumatology #Innovation

We’re excited to share that Nkarta will be presenting a poster at the upcoming American College of Rheumatology’s Convergence 2025 in Chicago! Our poster will feature new clinical data showing that NKX019, our investigational allogeneic off-the-shelf CAR-NK cell therapy, achieves robust B-cell depletion and immune reset in participants with non-Hodgkin lymphoma. We’ll also present preclinical results demonstrating the potential of NKX019 to deplete disease-driving B cells in autoimmune diseases. Join us at Hall F1 (Poster 14) and Booth 1801. Learn more: https://lnkd.in/gdXJ66ia #ACR25 #CellTherapy #AutoimmuneDisease #NKCells #Innovation #Biotech

Nkarta is studying how natural killer cells may advance new treatment approaches for autoimmune disease.

Our CEO Paul Hastings has been living with an autoimmune disease for 46 years. In a STAT First Opinion op-ed published today, he acknowledges the gamut of health, occupational, family and financial challenges facing people living with #autoimmuneconditions and discusses the promise of #celltherapy to upend the inadequate standard of care. In the STAT essay, he talks about his own struggles taking steroids as a teenager to manage his Crohn's disease and calls on drug developers to do more to ensure #clinicaltrial opportunities are available to those who are medically eligible and interested in participating. Read the full piece on STAT: https://lnkd.in/g6RgEySR Download the PDF here: https://lnkd.in/g62f22CF Vasculitis Foundation, National Scleroderma Foundation, Myositis Support and Understanding Association, Inc. (MSU), The Myositis Association, Lupus and Allied Diseases Association, Inc.